{"entity":{"id":"pelabresib","kind":"drug","name":"Pelabresib","aka":[],"tldr":"Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.","summary":"Pelabresib (CPI-0610) is a small-molecule drug developed by Novartis Pharmaceuticals. The sponsor describes its target as BET (bromodomain and extraterminal protein), which OnCo does not yet have a target page for. The sponsor states: A small-molecule BET protein inhibitor. ClinicalTrials.gov describes the intervention as: Small molecule inhibitor of bromodomain and extraterminal (BET) protein. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib). The largest, NCT06401356, plans to enrol 50 participants with primary completion expected 2027-06-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Pelabresib","url":"https://clinicaltrials.gov/search?intr=CPI-0610"},{"label":"Sponsor pipeline page","url":"https://www.novartis.com/research-development/novartis-pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["primary-myelofibrosis"],"sections":[],"technologies":[],"targets":["brd4"],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06401356"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CPI-0610","modality":"small molecule","mechanism":"A small-molecule BET protein inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pelabresib/","neighbours":{"cancer":[{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"target":[{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"trial":[{"id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/"}]}}